Pfizer Oncology at the American Society of Clinical Oncology (ASCO) Meeting

ASCO 2008Analyst BriefingJune 2, 2008Forward-Looking Statements and Non-GAAP Financial Information• Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.• Also, discussions during this meeting may include certain financial measures that were not prepared in accordance with generally accepted accounting principles. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measurescan be found in Pfizer’s Current Reports on Form 8-K dated April 17, 2008. • These reports are available on our website at www.pfizer.com in the “Investors—SEC Filings” section.2Pfizer’s Emerging Leadership in OncologyAlison AyersWorld Wide Commercial LeaderPfizer Oncology Leadership TeamGarry NicholsonSeniSeni or Vice or Vice PrePre ss ident/General Mident/General M aa nagernagerAlison AyersCharles BaumCraig EaglePat AndrewsWW CommeWW Comme rrcc ial ial WW DeveloWW Develo pp mentmentWW MedWW Med iical Leadercal LeaderUS GeneraUS Genera l Managerl ManagerLeaderLeaderLeaderLeaderPfizer Regional Pfizer Regional Commercial OperatioCommercial Operatio nsnsMedical OperationsMedical Operations4Pfizer Therapeutic Area PrioritiesInvest to WinFirst or High Market High Best in ClassGrowthUnmet Need• Oncology• Pain• Immunology/Inflammation• Diabetes/Obesity• Alzheimer’s Disease• Schizophrenia 5Oncology R&D AchievementsIncrease in number of oncology R&D projects in past five years400%Ongoing or planned oncology studies 232Oncology compounds in clinical development 22Research budget dedicated to oncology22%6Pfizer’s Four Oncology Research PlatformsANTI-ANGIOGENESISIMMUNOTHERAPYBlocks growth of Reawakens immune tumor blood vesselssystemSIGNAL CYTOTOXIC/TRANSDUCTION POTENTIATORSINHIBITORSExploit defects Blocks cancer in repair and growth signalscycle cells7Advances in the Oncology Pipeline in the ClinicNumber of Compounds in Phase IPhase IIPhase IIIeach PhaseASCO 20081363ASCO 20079448Pfizer Oncology Clinical PortfolioTSP-1(CVX-045)*Platform KeyAng-2 AntAnti-Angiogenesis(CVX-060)*Transitions SinceASCO 2007Signal TransductionALK1 mAb(PF-3446962)ImmunotherapysVEGFR(PF-337,210)Cytotoxic/mRTKPotentiatorsP-Cad mAb(SU-14,813)(PF-3, 732,010)FAKPan-ErbBSutent®(PF-562,271)(PF-00299804)Sutent®C-MetEGFRvlll(PF-2,341,066)(CDX-110)Aromasin®AxitinibC-Met BUTremelimumab(AG-013,736)(PF-4217903)(CP-675,206)Camptosar®IGF-1R mAbHsp90TLR9(CP-751,871)(SNX 5422)(PF-3,512,676)Ellence ®CD40 mAbPARP*Pfizer Biotherapeutics and Bioinnovation Center(CP-870,893)AG-14,699CDK 4/6(PD-332991)CHK1(PF-477,736)AUR2(PF-3,814,73513634Phase IPhase IIPhase IIIApprovedRecent Oncology Licensing and AcquisitionsCompany/CompoundValue to Pfizer PortfolioAvant – licenseNovel vaccine in Phase IIb/III for GBM CDX-110 (EGFRvIII vaccine) High unmet medical needSerenex – acquisitionPhase I, novel mechanismSNX-5422 (Hsp90 inhibitor)Complementary to portfolioCovX – acquisition Two Phase I agents CVX 045 (thrombospondin), Novel anti-angiogenesis mechanisms CVX 060 (angiopoietin)Coley – acquisitionExpands vaccine development capabilityVaccine platform, TLR-7 and TLR-9 programsStrengthens immuno-oncology portfolio10